A fillip for the pharmaceutical sector

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

A fillip for the pharmaceutical sector

Case of the Year: Neurim v UK government

circadin.jpg

The result

SPCs can be obtained for second medical use patents

The impact

A bonus for pharma companies investing in the development of products for different uses

The Court of Justice of the EU has little to do with patents (at least for now). So when it does rule in one of the limited patent-related areas over which it has jurisdiction, IP attorneys await its rulings with perhaps greater trepidation than normal. It was only last year, after all, that the Court curbed the patentability of human embryonic stem cells in Brüstle, a ruling that clarified the directive on the legal protection of biotechnological inventions.

But this year the Court gave pharmaceutical companies something of a fillip in a dispute related to supplementary protection certificates (SPCs). This is a sui generis right that effectively extends the life of a patent on a specific pharmaceutical-type product by compensating the owner for the time spent obtaining regulatory approval to put it on the market.

At the end of 2009, a hearing officer at the UK Intellectual Property Office IPO refused to grant Neurim an SPC for its product Ciracadin (melatonin). Circadin is used to treat insomnia and the basic patent concerns the use of melatonin to correct a distortion or deficiency in the plasma melatonin profile of humans.

The Office said that because melatonin had already been marketed since 2001 (by CEVA Animal Health under the name Regulin), Neurim's product was not eligible for an SPC. In particular, the hearing officer said that the intended use of the medicinal product could not be taken into account when considering the relevance of an earlier marketing authorisation.

The patent owner took the case to the High Court. At first instance, Mr Justice Arnold upheld the IPO's decision but the Court of Appeal later referred five questions to Europe's highest court. Writing for the Court of Appeal, Lord Justice Jacob (as he was then), made it clear that he thought the lower court had got it wrong. If its finding was right, he said, then "the Regulation will not have achieved its key objects for large areas of pharmaceutical research: it will not be fit for purpose. Whether that is so or not is clearly a matter for the EU's highest court".

Now the Court of Justice of the EU has offered its support to Jacob's interpretation of the rules on SPCs.

"The mere existence of an earlier marketing authorisation obtained for a veterinary medicinal product does not preclude the grant of a supplementary protection certificate for a different application of the same product for which a marketing authorisation has been granted," said the Court, "provided that the application is within the limits of the protection conferred by the basic patent relied upon for the purposes of the application for the supplementary protection certificate."

The ruling was good news for Neurim and other pharmaceutical companies investing in the development of products for different uses. But like a number of Court of Justice rulings, it leaves questions unanswered. Is there, for example, a distinction between obtaining earlier marketing authorisation for veterinary use of a product and human use? While IP owners welcomed Neurim, it was far from being the last word on SPCs.

Case details

Neurim v UK government

Patent number: EP (UK) 0 518 468

Invention: Melatonin to treat insomnia (branded as Circadin)

Technology: Pharmaceuticals

Patent owner: Neurim Pharmaceuticals

Other party involved: UK IPO

Courts: Court of Justice of the EU following a referral by the Court of Appeal in London

For Neurim: Carpmaels & Ransford

For the UK government: S Ossowski and A Robinson as agents and Charlotte May

This case was selected as one of Managing IP’s Cases of the Year for 2012.

To see the rest, click on one of the cases below.

The 10 cases of the year

A fillip for the EU pharmaceutical sector

Relief for trade mark owners in red sole saga

Australian TV streaming service held to be illegal

Smartphone war hits front page in the US

Liberalising the EU’s software market

India allows parallel imports

Victory for fair dealing in Canada

Lacoste loses its trade mark in China

Google prevails in Android attack

EU test case clarifies class headings

Ten you might have missed

Canada: Ambiguous claims can invalidate patents

Russia: Certainty on parallel imports

Italy: TV formats win copyright for the first time

First FRAND cases litigated worldwide

Monsanto loses in Brazil

Data exclusivity backed by Mexican courts

China: A shift over OEM manufacturing

Authors in the US able to reclaim joint copyrights

Germany: Knitted trainers a sign of the future

India: Financial Times loses trade mark

more from across site and SHARED ros bottom lb

More from across our site

Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Gift this article